We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fully Automated Blood-Based Assays Measure Biomarker for Neurodegenerative Diseases within 35 Minutes

By LabMedica International staff writers
Posted on 29 Mar 2023
Print article
Image: Fujirebio has launched the fully automated Lumipulse G NfL CSF and Lumipulse G NfL blood tests (Photo courtesy of Fujirebio)
Image: Fujirebio has launched the fully automated Lumipulse G NfL CSF and Lumipulse G NfL blood tests (Photo courtesy of Fujirebio)

Neurofilament light (NfL) is considered to be a promising biomarker for disease activity, progression, prognosis, and monitoring effectiveness of therapies in conditions such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease as well as in acute situations like traumatic brain injury (TBI). Now, researchers and clinical research professionals across the world can further study the clinical utility of this promising biomarker by using newly-launched biomarker tests that enable the quantitative measurement of NfL.

Fujirebio (Gent, Belgium) has expanded its assay menu in the field of neurodegenerative diseases by launching the fully automated Lumipulse G NfL CSF and Lumipulse G NfL Blood CLEIA (chemiluminescent enzyme immunoassay) assays for the LUMIPULSE G immunoassay systems. The assays enable the quantitative measurement of NfL in human Cerebrospinal fluid (CSF) and plasma/serum, respectively, in only 35 minutes. The assays are available for Research Use Only and will allow researchers and clinical research professionals to further examine the clinical utility of NfL in diverse disease conditions like multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease as well as TBI.

Laboratory professionals can opt for their preferred specimen matrix and measure NfL on the fully automated, random-access LUMIPULSE G platform. This standardized immunoassay system family is widely available and used by routine labs which are active in the field of neurological diseases with its current assay menu. The LUMIPULSE G platform fulfills the required throughput, quality, and regulatory requirements for supporting potential future routine use of NfL apart from the existing portfolio.

“In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” said Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative disease field as quickly as possible.”

Related Links:
Fujirebio

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more